GBT Market Share Analysis for May 2026

discover the commonalities and differences between biologics vs. biosimilars — especially when it comes to cost.

Health > Biotechnology and Pharmaceuticals

Domaingbt.com

Year Founded2011

Employees201 - 500

Annual Revenue$200M - $500M

GBT

GBT (including company regionals)

gbt.com

See more website traffic and engagement information

GBT Revenue up to May 2026 is 200M - 500M

revenue generated by GBT top domains

GBT top domains revenue over 3 years

Revenue for GBT top domains

gbt.com200M - 500M

See more with Sales Intelligence

Total visits to GBT's top domains

Understand GBT market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

gbt.com119

See more with Sales Intelligence

Avg. visit duration in GBT's top domains

Analyze GBT engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on GBT's top domains

See how GBT keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

gbt.com1.00

See more with Sales Intelligence

GBT top competitors by domain

Top similar sites in May 2026, ranked by their affinity

milfordhospital.orgCompany NameMilford HospitalEmployees501 - 1000HQUnited States, Connecticut, MilfordAnnual revenue$25M - $50MTotal visits--Health > Medicine

Top technologies used by GBT

These are the website technologies, by industry, used by GBT top domains

Advertising (5)

DoubleClick

Email Services (4)

G Suite

Content Management System (2)

WordPress

Marketing (2)

Google Marketing Platform

More Technologies

11

See all

News & Signals from GBT

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsGlobal Blood Therapeutics Inc. hired Love as CEO on Jan 1st '14.So, in 2014, when Dr. Love, who had since retired, was tapped to join GBT, he was both as an industry veteran and an experienced CEO.

NewsGlobal Blood Therapeutics Inc. is developing treatments for beta thalassemia and sickle cell disease.Pfizer terminated a deal that Syros Pharmaceuticals made with Global Blood Therapeutics to develop treatments for beta thalassemia and sickle cell disease.

NewsPfizer-BioNTech acquires Global Blood Therapeutics Inc. for $5.4B.Vaccine-maker Pfizer-BioNTech will acquire Global Blood Therapeutics, which specializes in blood disorder treatments, for $5.4 billion.